Drugs / Reltecimod
Reltecimod
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01166984 | Sep 2010 → Jun 2011 | — | Atox Bio Ltd | Completed | No outcome recorded |
| Phase 32 trials · 1 missed | ||||||
| Phase 3 | NCT03403751 | May 2018 → Dec 2019 | acute kidney injury, necrotizing soft tissue infection, peritonitis | Atox Bio Ltd | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT02469857 | Dec 2015 → Aug 2019 | fournier gangrene, necrotizing fasciitis, necrotizing soft tissue infection | Atox Bio Ltd | Completed | Missed primary |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01417780 Comparator | Dec 2011 → Sep 2012 | necrotizing soft tissue infection | Atox Bio Ltd | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Reltecimod | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03403751 ↗ |
| Known as | AB 103 | “A Novel Immune Modulator for Patients With Necrotizing Soft Tissue Infections (NSTI): Results of a Multicenter, Phase 3 Randomized Controlled Trial of Reltecimod (AB 103).” PMID 32657946 ↗ Sep 2020 |
| Known as | AB103 sodium | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989950 ↗ |
| Known as | RELTECIMOD SODIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989950 ↗ |
| Action | Inhibit | “A Peptide Antagonist” NCT01166984 ↗ |
| Modality | Peptide | “A Peptide Antagonist” NCT01166984 ↗ |
| Route | Intravenous | “Single intravenous infusion at doses of 7.5 µg/kg, 37.5 µg/kg, 150 µg/kg, or 450 µg/kg administered over approximately 10 minutes” NCT01166984 ↗ |
| Target | CD28 | “AB103 is a peptide mimetic of the T-lymphocyte receptor, CD28.” PMID 24740134 ↗ Jun 2014 |